创新药概念持续活跃 百济神州等多股创历史新高 智通财经4月30日电，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制 药、华东医药、恒瑞医药等涨幅靠前。消息面上，2025年一季度，已经出现了超20笔涉及中国药企全球 授权的交易，BD交易有望在今年再创新高。 ...

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

智通财经4月29日电，科伦药业(002422.SZ)公告称，科伦药业发布2025年第一季度报告，营业收入为 43.89亿元，同比下降29.42%；归属于上市公司股东的净利润为5.84亿元，同比下降43.07%。 科伦药业：一季度净利润为5.84亿元 同比下降43.07% ...

Financial Performance - The company's revenue for Q1 2025 was ¥4,389,897,045, a decrease of 29.42% compared to ¥6,219,417,413 in the same period last year[5] - Net profit attributable to shareholders was ¥584,242,512, down 43.07% from ¥1,026,188,176 year-on-year[5] - Basic and diluted earnings per share were both ¥0.37, reflecting a decline of 44.78% from ¥0.67 in the same period last year[5] - Total operating revenue decreased to ¥4,389,897,045, down 29.5% from ¥6,219,417,413 in the previous period[24] - Net profit for the period was ¥659,587,476, representing a 48.7% decrease from ¥1,285,801,413 in the prior year[25] - The total comprehensive income for the period was CNY 653,323,410, a decrease from CNY 1,284,956,201 in the previous period[26] Cash Flow - The net cash flow from operating activities decreased by 64.86%, amounting to ¥449,384,244 compared to ¥1,278,763,116 in the previous year[10] - Net cash flow from operating activities was CNY 449,384,244, significantly lower than CNY 1,278,763,116 in the previous period[28] - Cash inflow from operating activities totaled CNY 5,184,117,253, compared to CNY 6,561,069,026 in the previous period[27] - Cash outflow from operating activities was CNY 4,734,733,009, down from CNY 5,282,305,910 in the previous period[27] - Net cash flow from investing activities was negative CNY 690,071,360, a decline from positive CNY 670,633,809 in the previous period[28] - Cash inflow from investing activities was CNY 4,018,350,908, compared to CNY 1,772,849,022 in the previous period[28] - Cash outflow from financing activities was CNY 1,063,394,172, down from CNY 1,512,332,605 in the previous period[28] - The ending balance of cash and cash equivalents was CNY 4,075,118,403, down from CNY 6,231,493,756 in the previous period[28] Assets and Liabilities - Total assets increased by 1.37% to ¥37,826,228,881 from ¥37,316,259,482 at the end of the previous year[5] - Current liabilities totaled ¥9,092,533,232, slightly down from ¥9,137,877,768, a decrease of 0.5%[23] - Long-term borrowings decreased to ¥196,000,000 from ¥342,000,000, a reduction of 42.8%[23] - The company's equity attributable to shareholders increased to ¥23,094,459,078, up from ¥22,479,520,446, a rise of 2.7%[23] Investment and Income - Investment income decreased by 45.17%, amounting to ¥61,314,415 compared to ¥111,835,302 in the previous year[9] - The company reported an increase in investment income to ¥61,314,415 from ¥111,835,302, a decline of 45%[25] - The company reported a total investment of 10,000 million in structured deposits with a floating return of 2.50%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,389[11] - Liu Gexin holds 23.72% of the shares, totaling 379,128,280 shares, with 284,346,210 shares under lock-up and 106,014,000 shares pledged[11] - The second largest shareholder, Yaan State-owned Assets Management Co., Ltd., holds 6.07% of the shares, totaling 96,983,174 shares, with 34,010,800 shares pledged[11] - The top 10 shareholders collectively hold significant stakes, with the largest shareholder holding nearly 24%[11] - The company has no preferred shareholders as of the reporting period[12] Research and Development - The company has received approval for its subsidiary's PD-L1 antibody, indicating progress in its product pipeline[18] - A new drug application for the core product, Boduqumab, has been accepted by the National Medical Products Administration, highlighting ongoing R&D efforts[18] - The company has established an exclusive licensing agreement for SKB378/HBM9378, which may enhance its market position[18] Financial Management - The company did not engage in any significant financial management activities during the reporting period[12] - The company plans to continue its financial management strategy, including potential future entrusted wealth management plans[21] Miscellaneous - The company reported a total of 424,982,000.00 in financial assets, with a significant increase in cash and cash equivalents to 4,092,787,913.00 from 3,973,908,715.00[21] - The trading financial assets rose to 2,231,249,987.00, up from 1,921,163,411.00, indicating a growth of approximately 16.2%[21] - Accounts receivable decreased slightly to 4,726,326,218.00 from 4,795,035,595.00, reflecting a reduction of about 1.4%[21] - Inventory levels increased to 3,827,874,323.00 from 3,800,617,271.00, showing a growth of approximately 0.7%[21] - The company completed the cancellation of repurchased shares, indicating a strategic move to enhance shareholder value[19] - The company's first quarter report was not audited[29]

Group 1 - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7459.13 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 3.80% over the past month, increased by 3.37% over the past three months, and has risen by 0.20% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.67%), WuXi AppTec (16.06%), Pian Zai Huang (6.84%), Yunnan Baiyao (5.71%), Kelun Pharmaceutical (4.69%), New Horizon (3.81%), East China Pharmaceutical (3.6%), Shanghai Raist (3.44%), Fosun Pharma (3.37%), and Changchun High-tech (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.43% from the Shanghai Stock Exchange and 36.57% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.67%), pharmaceutical and biotechnology services (21.27%), traditional Chinese medicine (19.68%), and biological drugs (16.38%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index [2]

Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. is set to hold its 2024 annual performance briefing on May 6, 2025, to provide insights into its financial performance and address investor inquiries [1][4]. Group 1: Event Details - The annual performance briefing will take place from 15:00 to 17:00 on May 6, 2025, via a text Q&A format on the Jinmen Finance platform [1]. - Investors can participate in the briefing through a designated online link [2]. Group 2: Participants - Key attendees at the briefing will include Chairman Liu Gexin, Independent Director Ren Shichi, Vice General Manager and CFO Lai Degui, Vice General Manager and Board Secretary Feng Hao, Sales Head Ge Tao, CFO of Kelun Botai and Board Secretary Zhou Zejian, and Deputy General Manager and Board Secretary of Chuaning Bio Gu Xiang [2]. Group 3: Investor Engagement - The company is actively soliciting questions from investors prior to the event to ensure that common concerns are addressed during the briefing [2].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）将于 2025 年 5 月 6 日（星 期二）下午 15:00-17:00 在进门财经以文字问答的形式举行科伦药业 2024 年度业 绩说明会。 投资者可以通过以下两种方式参与： 1）电脑端参会：https://s.comein.cn/syfe7cqa； 2）登录进门财经 APP/进门财经小程序，搜索"002422"、"科伦药业"或者 扫描二维码，进入"科伦药业（002422.SZ）2024 年度网上业绩说明会"，点击进 入会议。 证券代码：002422 证券简称：科伦药业 公告编号：2025-037 四川科伦药业股份有限公司 关于召开 2024 年度网上业绩说明会的公告 为广泛听取投资者的意见和建议，解答投资者关切的问题，现就公司2024年 度业绩说明会提前向投资者公开征集问题。提问通道自本公告发出之日起开放， 投资者通过上述参与方式进入"科伦药业2024年度网上业绩说明会"页面进行 提问，公司将在本次业绩说明会上对投资者普遍关注的问题进行回答。 1 欢迎广大投资者积 ...

Group 1: Pharmaceutical Industry Development - The pharmaceutical industry in Yuechi County has achieved an annual output value exceeding 100 million yuan, with a market share of over 70% for the raw material drug Ampicillin Sodium [1] - The county has established the largest raw material drug production base in the province, with 64 enterprises across six categories, forming a collaborative development pattern [1] - The county aims to reach an industry scale of 40 billion yuan by 2027, 60 billion yuan by 2030, and 100 billion yuan by 2035, with plans to accelerate the establishment of a national-level concentrated production base for raw materials [2] Group 2: Electrical Industry Development - Yuechi County has 30 electrical enterprises and over 1,000 construction teams, undertaking more than 1,300 projects annually, generating approximately 5 billion yuan in labor income [2] - The county is transitioning from labor output to large-scale manufacturing in the electrical industry, which is gaining momentum [2] Group 3: Agricultural and Tourism Integration - Yuechi County has transformed 820,000 acres of high-standard farmland, with a grain planting area exceeding 1.1 million acres, ranking among the top grain-producing counties in the province [2] - The county received nearly 3 million tourists in the first quarter of this year, generating a tourism revenue of 2.2 billion yuan [3]

Revenue and Profit - The total operating revenue for the year reached 21.812 billion yuan, a year-on-year increase of 1.67% [2] - The net profit attributable to shareholders was 2.936 billion yuan, up 19.53% year-on-year, while the net profit after deducting non-recurring items was 2.902 billion yuan, an increase of 22.66% [2] - In the fourth quarter, operating revenue was 5.024 billion yuan, a decrease of 12.03% year-on-year, and the net profit attributable to shareholders was 465 million yuan, down 5.65% year-on-year, indicating quarterly fluctuations [2] Profitability - The gross profit margin was 51.69%, a decrease of 1.41 percentage points compared to the same period last year, while the net profit margin increased by 24.94% to 15.41% [3] - The ratio of selling, administrative, and financial expenses to revenue was 22.31%, a decrease of 17.82% year-on-year, reflecting optimization in expense control [3] Cash Flow and Debt - The company's cash and cash equivalents amounted to 3.974 billion yuan, a decrease of 15.01% year-on-year [4] - Accounts receivable stood at 4.795 billion yuan, an increase of 2.40% year-on-year, with a notable ratio of accounts receivable to profit at 163.32% [4] - Interest-bearing debt was 3.67 billion yuan, significantly reduced by 46.77% year-on-year, indicating an optimized financing structure [4] Main Business Composition - Revenue from non-infusion products was 10.3 billion yuan, accounting for 47.22% of total revenue, with a gross profit margin of 43.91% [5] - Revenue from infusion products was 8.912 billion yuan, making up 40.86% of total revenue, with a gross profit margin of 60.16% [5] - Revenue from R&D projects was 1.895 billion yuan, representing 8.69% of total revenue, with a gross profit margin of 65.50% [5] - International business revenue reached 2.886 billion yuan, a year-on-year increase of 11.49%, indicating growth potential in overseas markets [5] R&D and Innovation - The company invested significantly in R&D, with 34 generic and improved new drugs approved for production and 50 applications submitted [6] - Progress in innovative drug development is on track, with multiple products entering clinical research stages [6] - The company holds 2,860 valid patent applications, with 1,997 already authorized, and has two innovative drugs, Lukanosatuzumab and Tagolisumab, approved for market [6]